teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 8 Projects Releases Packages Wiki Activity Actions 1

auto-fix: strip 5 broken wiki links

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-03-16 15:49:30 +00:00
parent d8c2a277f1
commit c5805e7519
3 changed files with 5 additions and 5 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

4
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -49,13 +49,13 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* *Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated. At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* *Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16*
The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (82% below list) with narrow eligibility criteria requiring comorbidities (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). This targets ~10% of Medicare beneficiaries—specifically the high-risk population where downstream savings (24% kidney disease progression reduction, cardiovascular protection) offset drug costs under capitation. The narrow eligibility is the mechanism that changes the cost-effectiveness calculus: inflationary impact depends on population breadth, not just drug price. The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (82% below list) with narrow eligibility criteria requiring comorbidities (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). This targets ~10% of Medicare beneficiaries—specifically the high-risk population where downstream savings (24% kidney disease progression reduction, cardiovascular protection) offset drug costs under capitation. The narrow eligibility is the mechanism that changes the cost-effectiveness calculus: inflationary impact depends on population breadth, not just drug price.

2
domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
View file

@ -49,7 +49,7 @@ No data yet on whether payment model affects persistence—does being in an MA p
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* *Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16*
The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2026 for tirzepatide) removes most financial barriers to persistence for the eligible population. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence. The OOP cap may improve persistence rates specifically in Medicare, though this remains untested. The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2026 for tirzepatide) removes most financial barriers to persistence for the eligible population. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence. The OOP cap may improve persistence rates specifically in Medicare, though this remains untested.

4
domains/internet-finance/metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md
View file

@ -62,13 +62,13 @@ Cloak raised only $1,455 against a $300,000 target (0.5% of target), entering re
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-03-05-futardio-launch-phonon-studio-ai]] | Added: 2026-03-16* *Source: 2026-03-05-futardio-launch-phonon-studio-ai | Added: 2026-03-16*
Phonon Studio AI launch failed to reach its $88,888 target and entered refunding status, demonstrating that not all futarchy-governed raises succeed. The project had demonstrable traction (live product, 1000+ songs generated, functional token mechanics) but still failed to attract sufficient capital, suggesting futarchy capital formation success is not uniform across project types or market conditions. Phonon Studio AI launch failed to reach its $88,888 target and entered refunding status, demonstrating that not all futarchy-governed raises succeed. The project had demonstrable traction (live product, 1000+ songs generated, functional token mechanics) but still failed to attract sufficient capital, suggesting futarchy capital formation success is not uniform across project types or market conditions.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-14-futardio-launch-nfaspace]] | Added: 2026-03-16* *Source: 2026-03-14-futardio-launch-nfaspace | Added: 2026-03-16*
NFA.space launched on futard.io with $125,000 target, demonstrating futarchy-governed fundraising for physical art RWA marketplace. Project has pre-existing traction: 1,895 artists from 79 countries, 2,000+ artworks sold, $150,000 historical revenue, $5,000 MRR, 12.5% repeat purchase rate. This shows futarchy ICO platform attracting projects with demonstrated product-market fit, not just speculative launches. NFA.space launched on futard.io with $125,000 target, demonstrating futarchy-governed fundraising for physical art RWA marketplace. Project has pre-existing traction: 1,895 artists from 79 countries, 2,000+ artworks sold, $150,000 historical revenue, $5,000 MRR, 12.5% repeat purchase rate. This shows futarchy ICO platform attracting projects with demonstrated product-market fit, not just speculative launches.